A Phase 2 Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Telios Pharma, Inc.
Start Date
May 23, 2024
End Date
June 14, 2029
Administered By
Duke Cancer Institute
Awarded By
Telios Pharma, Inc.
Start Date
May 23, 2024
End Date
June 14, 2029